Publications by authors named "Ching Fai Fung"

Endoplasmic reticulum (ER) chaperone Prolyl 4-hydroxylase, beta polypeptide (P4HB) has previously been identified as a novel target for chemoresistance in glioblastoma multiforme (GBM). Yet its functional roles in glioma carcinogenesis remain elusive. In clinical analysis using human glioma specimens and Gene Expression Omnibus (GEO) profiles, we found that aberrant expression of P4HB was correlated with high-grade malignancy and an angiogenic phenotype in glioma.

View Article and Find Full Text PDF

Isocitrate dehydrogenase 1 (IDH1) mutation is an important prognostic marker in glioma. However, its downstream effect remains incompletely understood. Long non-coding RNAs (lncRNAs) are emerging as important regulators of tumorigenesis in a number of human malignancies, including glioma.

View Article and Find Full Text PDF

Glioblastoma multiforme (GBM) is the commonest primary brain tumour in adults characterized by relentless recurrence due to resistance towards the standard chemotherapeutic agent temozolomide (TMZ). Prolyl 4-hydroxylase, beta polypeptide (P4HB), an endoplasmic reticulum (ER) chaperone, is known to be upregulated in TMZ-resistant GBM cells. MicroRNAs (miRNAs) are non-protein-coding transcripts that may play important roles in GBM chemoresistance.

View Article and Find Full Text PDF
Article Synopsis
  • Long non-coding RNAs (lncRNAs) are increasingly recognized in cancer research for their role in cancer development and prognosis, specifically in glioblastoma multiforme (GBM).
  • A study analyzed lncRNA expression in 213 GBM tumors from The Cancer Genome Atlas (TCGA), identifying a six-lncRNA signature linked to overall survival, allowing classification of patients into high-risk and low-risk groups.
  • This signature was validated across multiple data sets and was found to be a reliable prognostic tool, independent of patient age and specific genetic markers, highlighting the significance of lncRNAs in GBM.
View Article and Find Full Text PDF

Background: Cranionasal resection was first described in 1997 for the surgical resection of olfactory neuroblastoma. The endoscopic transnasal approach is used in cranionasal resection to replace the more invasive craniofacial resection. It has the advantages of avoiding the facial wound and its associated pain, swelling, and scar.

View Article and Find Full Text PDF